| Hepatitis |
| Not yet recruiting | 4 | 1500 | RoW | Vitamin D3 | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Carcinoma, Hepatocellular | 06/16 | 12/26 | | |
NCT03084250: The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC |
|
|
| Active, not recruiting | 4 | 150 | RoW | Peginterferon Alfa-2A, Pegasys, Adefovir, entecavir,tenofovir, either of them | Shanghai Nanhui Nanhua Hospital | Hepatitis B | 04/23 | 12/23 | | |
NCT02031133: Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C |
|
|
| Active, not recruiting | 2 | 10 | US | Miravirsen | Santaris Pharma A/S | Hepatitis C | 01/17 | 01/17 | | |
NCT00096811: Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program |
|
|
| No Longer Available | N/A | | RoW | Entecavir, Baraclude | Bristol-Myers Squibb | Hepatitis B, Chronic Disease | 08/08 | 08/08 | | |
NCT02011932: Prospective Observational Study of Disease Progression in Chronic Hepatitis C |
|
|
| Active, not recruiting | N/A | 133 | RoW | | Beijing YouAn Hospital | Hepatitis C, Chronic, Disease Progression, Liver Cirrhosis | 06/11 | 07/30 | | |
| No Longer Available | N/A | | Europe, RoW | Telaprevir + peginterferon alfa + ribavirin, experimental, peginterferon alfa + ribavirin | Janssen-Cilag International NV | Hepatitis C | | | | |
|
|
|
|
|
|
|
|
|
NCT02097966: EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C |
|
|
| No Longer Available | N/A | | Europe | Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin | Bristol-Myers Squibb | Chronic Hepatitis C | | | | |
|
|
|
NCT02161939: A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C |
|
|
| No Longer Available | N/A | | US | Daclatasvir (BMS-790052), Sofosbuvir | Bristol-Myers Squibb | Chronic Hepatitis C | | | | |
|
NCT01306071: Observational Study of Persons With Hepatitis B Virus Infection in North America |
|
|
| Recruiting | N/A | 200 | US | | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative | | | | |
| Not yet recruiting | N/A | 103 | RoW | Daclatasvir and Asunaprevir, Daclatasvir and Asunaprevir combined treatment for 24 weeks | Sang Gyune Kim, Seoul National University Boramae Hospital, Severance Hospital, Inha University Hospital, Korea University, Gachon University Gil Medical Center, Hanyang University Seoul Hospital, Ewha Womans University Mokdong Hospital, Bristol-Myers Squibb | Chronic Hepatitis C | 12/18 | 12/22 | | |
NCT02793791: Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients |
|
|
| Not yet recruiting | N/A | 30 | RoW | minimally invasive ablation therapies | Shandong Cancer Hospital and Institute | Dysplastic Nodule of Liver, Chronic Hepatitis B | 12/19 | 12/22 | | |
NCT02461979: The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis |
|
|
| Recruiting | N/A | 50 | RoW | The VDR genotype | Sherief Abd-Elsalam, Tanta University | Liver Cancer | 12/22 | 12/22 | | |
NCT03097952: "Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu |
|
|
| Recruiting | N/A | 20000 | RoW | | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Hepatitis B， Chronic | 12/30 | 12/30 | | |